Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-2010 · 1 trial · 2 indications
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next dose.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
ORR is defined as a confirmed complete response (CR: Disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR).
| Arm | Type | Description |
|---|---|---|
| Part 1: Safety Lead-In Cohort | EXPERIMENTAL | Participants will receive MK-2010 in combination with sac-TMT. |
| Part 2: Signal-Finding Cohorts | EXPERIMENTAL | Participants will receive MK-2010 in combination with sac-TMT at the dose determined in Part 1. |
| Name | Type | Description |
|---|---|---|
| MK-2010 | BIOLOGICAL | Administered as an intravenous (IV) infusion |
| Sacituzumab tirumotecan | BIOLOGICAL | Administered as an IV infusion |
| Histamine H1 Receptor Antagonist | DRUG | Administered as a premedication per the approved product label |
| Histamine H2 Receptor Antagonist | DRUG | Administered as a premedication per the approved product label |
| Acetaminophen (or equivalent) | DRUG | Administered as a premedication per the approved product label |
| Dexamethasone (or equivalent) | DRUG | Administered as a premedication per the approved product label |
| Steroid mouthwash (dexamethasone or equivalent) | DRUG | Administered orally per the approved product label as a rescue medication |
| Epinephrine | DRUG | Administered for emergency use per the approved product label |
Inclusion Criteria: * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * If human immunodeficiency virus (HIV)-infected, has well-controlled HIV on antiretroviral therapy (ART) * If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) vira...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MK-2010 is an investigational monoclonal antibody being developed for the treatment of advanced solid tumors. It is currently in Phase 2 clinical development, and the ongoing trial is studying its use in participants with advanced solid tumors or malignant neoplasms.
MK-2010 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting a Phase 2 clinical trial of MK-2010 in advanced solid tumors.
MK-2010 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for the treatment of advanced solid tumors.
MK-2010 is being studied in a Phase 2 clinical trial with the identifier NCT07785609. This trial is titled 'A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors' and is planned to enroll 200 participants aged 18 years and older.
Yes, MK-2010 is being studied in combination with sacituzumab tirumotecan (Sac-TMT) in a Phase 2 clinical trial for participants with advanced solid tumors. The trial is not yet recruiting and is designed as a controlled study with 200 planned participants.